Origin Therapeutics Holdings (XCNQ:ORIG) EV-to-FCF : 4.90 (As of Jun. 09, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Origin Therapeutics Holdings's Enterprise Value is C$-3.65 Mil. Origin Therapeutics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was C$-0.75 Mil. Therefore, Origin Therapeutics Holdings's EV-to-FCF for today is 4.90.

The historical rank and industry rank for Origin Therapeutics Holdings's EV-to-FCF or its related term are showing as below:

XCNQ:ORIG' s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.9
Current: 4.9

During the past 2 years, the highest EV-to-FCF of Origin Therapeutics Holdings was 4.90. The lowest was 0.00. And the median was 0.00.

XCNQ:ORIG's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 21.99 vs XCNQ:ORIG: 4.90

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-09), Origin Therapeutics Holdings's stock price is C$0.025. Origin Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was C$-0.053. Therefore, Origin Therapeutics Holdings's PE Ratio for today is At Loss.

Origin Therapeutics Holdings EV-to-FCF Historical Data

The historical data trend for Origin Therapeutics Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Origin Therapeutics Holdings EV-to-FCF Chart

Origin Therapeutics Holdings Annual Data

Trend

Sep21

Sep22

EV-to-FCF

2.73

Origin Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EV-to-FCF	Get a 7-Day Free Trial				2.20	2.73	4.30	2.44	2.22

Competitive Comparison of Origin Therapeutics Holdings's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Origin Therapeutics Holdings's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's EV-to-FCF falls into.

Origin Therapeutics Holdings EV-to-FCF Calculation

Origin Therapeutics Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	-3.649	/	-0.745
	=	4.90

Origin Therapeutics Holdings's current Enterprise Value is C$-3.65 Mil.
Origin Therapeutics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.75 Mil.

Origin Therapeutics Holdings (XCNQ:ORIG) EV-to-FCF Explanation

Origin Therapeutics Holdings's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.025	/	-0.053
	=	At Loss

Origin Therapeutics Holdings's share price for today is C$0.025.
Origin Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.053.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Origin Therapeutics Holdings EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.